secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001437749-25-006907
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart initiates Phase 1 trial for oral norovirus vaccine; topline data expected mid-2025
--------------------------------------------------------------------------------

- Phase 1 open-label dose-ranging trial evaluating second-generation oral norovirus pill vaccine vs first-generation constructs.
- Topline data expected as early as mid-2025.
- If successful, Phase 2 could start H2 2025, Phase 3 as early as 2026, subject to partnership or other funding.
- No vaccines currently approved for norovirus; Vaxart's oral pill is the only clinical-stage candidate.
- CEO Steven Lo cites urgent public health need as norovirus spreads globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925006907/0001437749-25-006907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925006907/vxrt20250310_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer